Detalhe da pesquisa
1.
Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2.
Gynecol Oncol
; 161(3): 668-675, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33752918
2.
Evaluation of absorption, distribution, metabolism, and excretion of [14C]-rucaparib, a poly(ADP-ribose) polymerase inhibitor, in patients with advanced solid tumors.
Invest New Drugs
; 38(3): 765-775, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31250355
3.
Evaluation of in vitro absorption, distribution, metabolism, and excretion and assessment of drug-drug interaction of rucaparib, an orally potent poly(ADP-ribose) polymerase inhibitor.
Xenobiotica
; 50(9): 1032-1042, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-32129697
4.
A survey of renal impairment pharmacokinetic studies for new oncology drug approvals in the USA from 2010 to early 2015: a focus on development strategies and future directions.
Anticancer Drugs
; 28(7): 677-701, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28542036
5.
Pharmacokinetic models for FcRn-mediated IgG disposition.
J Biomed Biotechnol
; 2012: 282989, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22665983
6.
Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib.
Clin Pharmacokinet
; 61(11): 1477-1493, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36107395
7.
Population pharmacokinetics of rucaparib in patients with advanced ovarian cancer or other solid tumors.
Cancer Chemother Pharmacol
; 89(5): 671-682, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35397664
8.
A phase 1, open-label, drug-drug interaction study of rucaparib with rosuvastatin and oral contraceptives in patients with advanced solid tumors.
Cancer Chemother Pharmacol
; 88(5): 887-897, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34370076
9.
Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors.
Clin Pharmacol Drug Dev
; 8(1): 107-118, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29799676
10.
Evaluation of Drug-Drug Interactions of Rucaparib and CYP1A2, CYP2C9, CYP2C19, CYP3A, and P-gp Substrates in Patients With an Advanced Solid Tumor.
Clin Transl Sci
; 12(1): 58-65, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30427584
11.
Population pharmacokinetics of humanized monoclonal antibody HuCC49deltaCH2 and murine antibody CC49 in colorectal cancer patients.
J Clin Pharmacol
; 47(2): 227-37, 2007 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-17244774
12.
Discovery of a daunorubicin analogue that exhibits potent antitumor activity and overcomes P-gp-mediated drug resistance.
J Med Chem
; 49(3): 932-41, 2006 Feb 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-16451059
13.
Pharmacodynamic Model of Hepcidin Regulation of Iron Homeostasis in Cynomolgus Monkeys.
AAPS J
; 18(3): 713-27, 2016 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-26917226
14.
Population pharmacokinetic-pharmacodynamic modeling of omecamtiv mecarbil, a cardiac myosin activator, in healthy volunteers and patients with stable heart failure.
J Clin Pharmacol
; 55(11): 1236-47, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25951506
15.
Modeling the pharmacokinetic-pharmacodynamic relationship of the monoclonal anti-macaque-IL-15 antibody Hu714MuXHu in cynomolgus monkeys.
Pharmacol Res Perspect
; 3(6): e00199, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27022472
16.
Plasma and cerebrospinal fluid pharmacokinetics of depsipeptide (FR901228) in nonhuman primates.
Cancer Chemother Pharmacol
; 54(1): 85-8, 2004 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-15042312
17.
Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects.
AAPS J
; 12(4): 729-40, 2010 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-20963535
18.
Pharmacokinetics of anti-hepcidin monoclonal antibody Ab 12B9m and hepcidin in cynomolgus monkeys.
AAPS J
; 12(4): 646-57, 2010 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-20737261
19.
Efflux of depsipeptide FK228 (FR901228, NSC-630176) is mediated by P-glycoprotein and multidrug resistance-associated protein 1.
J Pharmacol Exp Ther
; 313(1): 268-76, 2005 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-15634944
20.
Chemoresistance to depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentanone] is mediated by reversible MDR1 induction in human cancer cell lines.
J Pharmacol Exp Ther
; 314(1): 467-75, 2005 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-15833893